期刊
MOLECULAR THERAPY
卷 21, 期 7, 页码 1358-1368出版社
CELL PRESS
DOI: 10.1038/mt.2013.66
关键词
-
资金
- LABEX (excellence laboratory, Invest for the Future)
- DISTALZ programs (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease) programs
- Inserm
- CNRS
- IMPRT (Institut de Medecine Predictive et de RechercheTherapeutique, Lille)
- University of Lille 2
- Region Nord/Pas-de-Calais
- FEDER
- DN2M (VICTAUR)
- European Community
- MEMOSAD (FP7 contract) [200611]
- FRC (Fondation pour la Recherche sur le Cerveau)
- [ANR-08-MNPS-002/AMYTOXTAU]
Most models for tauopathy use a mutated form of the Tau gene, MAPT, that is found in frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and that leads to rapid neurofibrillary degeneration (NFD). Use of a wild-type (WT) form of human Tau protein to model the aggregation and associated neurodegenerative processes of Tau in the mouse brain has thus far been unsuccessful. In the present study, we generated an original sporadic tauopathy-like model in the rat hippocampus, encoding six Tau isoforms as found in humans, using lentiviral vectors (LVs) for the delivery of a human WT Tau. The overexpression of human WT Tau in pyramidal neurons resulted in NFD, the morphological characteristics and kinetics of which reflected the slow and sporadic neurodegenerative processes observed in sporadic tauopathies, unlike the rapid neurodegenerative processes leading to cell death and ghost tangles triggered by the FTDP-17 mutant Tau P301L. This new model highlights differences in the molecular and cellular mechanisms underlying the pathological processes induced by WT and mutant Tau and suggests that preference should be given to animal models using WT Tau in the quest to understand sporadic tauopathies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据